Uncategorized
Ideaya’s uveal melanoma drug exceeds success benchmark in late-stage trial
Ideaya’s late-stage data for a rare eye cancer drug has passed the company’s benchmark for success, bolstering expectations for a planned accelerated filing in the US.
The open-label Phase 2/3 uveal melanoma trial tested the …